Trastuzumab-Induced Tumor Microenvironment Changes in Early HER2+Breast Cancer

被引：0
|
作者：
Kennedy, Laura C.
Alvarez, Rebeca
Dintzis, Suzanne
Gadi, Vijayakrishna K.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-23-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-23-05
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    BREAST, 2015, 24 : S95 - S95
  • [32] The trastuzumab era: current and upcoming targeted HER2+breast cancer therapies
    Kreutzfeldt, Jordyn
    Rozeboom, Brett
    Dey, Nandini
    De, Pradip
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (04): : 1045 - 1067
  • [33] A gene expression signature that predicts for trastuzumab response in HER2+breast cancer
    Abukhdeir, Abde M.
    Najor, Matthew S.
    Turturro, Sanja B.
    Armstrong, Andrew R.
    McDonald, Andrew
    Fogg, Lou
    Cobleigh, Melody A.
    CANCER RESEARCH, 2018, 78 (04)
  • [34] Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2+breast cancer
    Said, Badr Id
    Chen, Hanbo
    Jerzak, Katarzyna J.
    Warner, Ellen
    Myrehaug, Sten
    Tseng, Chia-Lin
    Detsky, Jay
    Husain, Zain
    Sahgal, Arjun
    Soliman, Hany
    JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (01) : 177 - 183
  • [35] Trastuzumab-decorated nanoparticles for in vitro and in vivo tumor-targeting hyperthermia of HER2+breast cancer
    Almaki, Javad Hamzehalipour
    Nasiri, Rozita
    Idris, Ani
    Nasiri, Mahtab
    Majid, Fadzilah Adibah Abdul
    Losic, Dusan
    JOURNAL OF MATERIALS CHEMISTRY B, 2017, 5 (35) : 7369 - 7383
  • [36] Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
    Ljubica Vazdar
    Ivo Darko Gabrić
    Ivan Kruljac
    Hrvoje Pintarić
    Robert Šeparović
    Lora Stanka Kirigin Biloš
    Mirjana Pavlović
    Ana Tečić Vuger
    Mario Štefanović
    Scientific Reports, 11
  • [37] HER2 Ile655Val polymorphism and the trastuzumab-induced cardiotoxicity in women HER2 positive breast cancer
    Sanchez Ramos, J. G.
    Davila-Fajardo, C. L.
    Burillo, F.
    Gomez Pena, C.
    Martinez Gonzalez, L. J.
    Correa Vilchez, C.
    Carmona Saez, P.
    Moreno Escobar, E.
    Blancas, I.
    Fernandez, J. J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 662 - 662
  • [38] Detection of Early Sub-Clinical Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients
    Dores, Helder
    Abecasis, Joao
    Correia, Maria Joao
    Gandara, Filipa
    Fonseca, Candida
    Azevedo, Jose
    Arroja, Isabel
    Martins, Ana
    Mendes, Miguel
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2013, 100 (04) : 328 - 332
  • [39] STAT6 expression and trastuzumab resistance in HER2+breast cancer.
    Cobleigh, Melody A.
    DiScala, Molly
    Najor, Matthew S.
    Yung, Timothy
    Abukhdeir, Abde M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
    Vazdar, Ljubica
    Gabric, Ivo Darko
    Kruljac, Ivan
    Pintaric, Hrvoje
    Separovic, Robert
    Bilos, Lora Stanka Kirigin
    Pavlovic, Mirjana
    Vuger, Ana Tecic
    Stefanovic, Mario
    SCIENTIFIC REPORTS, 2021, 11 (01)
12345